A brief history of amyloidosis goes back to autopsies of the seventeenth century reporting a waxing substance (Cordier, [@B2]). Later, in the middle of the nineteenth century, Rudolph Virchow described an "amyloid" (starch, *amulon*, Greek, *amylum*, Latin) degeneration and infiltration of the lungs within alveoli and small vessels in a patient who presented with systemic amyloidosis (heart, lungs, liver, and kidneys; Cordier, [@B2]). What amyloid-related diseases share is a common molecular ternary structure which involves abnormal aggregation of numerous widespread copies of the same protein into well-ordered filamentous β-sheet rich structures (Friedman, [@B3]) known as amyloid fibrils of 10--12 nm diameters (Plante-Bordeneuve and Said, [@B9]). This abnormal accumulation of amyloid oligomers, protofibrils, or fibrils is considered to be one of the major contributor to neurodegeneration and the hallmark of Alzheimer\'s (AD) and Parkinson\'s diseases (Arora et al., [@B1]). A primary cause underlying these accumulations is the folding of polypeptide chains to specific three-dimensional proteins in abnormal ways (Selkoe, [@B12]). The progressive misfolding of specific proteins into aggregation may lead to cell alteration or death. Aggregated forms share many characteristics. One of them is that amyloid deposits show specific optical behavior such as birefringence on binding dyes (Congo red). The systemic distribution of amyloidoses may produce extracellular deposits in multiple organs (Joachim et al., [@B6]). In this paper, Clos, Kayed, and Lasagna-Reeves present a novel perspective about the relation of dermis--epidermis--brain and offer a review about amyloid deposits that are central to the strong "brain--skin" connection. This connection starts as early as the sharing a joint embryological origin. Common multipotent embryonic progenitor stem cells from the ectoderm on the surface of the post-gastrulation embryo receive specific signaling from their environment that instruct them to commit to a particular differentiation program which will give rise to the nervous system or skin epithelium (Quan and Hassan, [@B10]; Fuchs, [@B4]). Clos, Kayed, and Lasagna-Reeves highlight common "brain--skin" pathophysiological disorders such as the role of presenilin 1 (PS-1) for proteolytic processing of the amyloid precursor protein (APP) which is altered in AD; alteration also found in skin cancers (Xia et al., [@B14]; Kang et al., [@B7]). They also draw parallels between neurodegenerative disorders of Parkinson\'s disease (Lewy bodies, α-synuclein, melanin) and amyotrophic lateral sclerosis (ALS inclusion bodies) which share common features with skin diseases (Hays et al., [@B5]). In addition, Clos, Kayed, and Lasagna-Reeves are describing transdermal route-of-entry as an elected administration route for potential medications to patients with neurodegenerative diseases such as Rivastigmine (AD and Parkinson), Rotigotine (Parkinson). A favorable coefficient of partition (physiologically based pharmacokinetics, PBPK; Thrall et al., [@B13]) to the brain via the skin vector seems promising for potential drugs targeting the brain (Zhao et al., [@B15]). In PDAPP transgenic mice, the immunization with the 42-amino-acid form of the peptide (Aβ42) prevents the development of cerebral β-amyloid-plaque formation, neuritic dystrophy and astrogliosis (Schenk et al., [@B11]); the transdermal route has also been successfully used without detrimental side effects such as T cell infiltration and cerebral microhemorrhage (Nikolic et al., [@B8]). Occurrence of the systemic deposition of β-amyloid protein in multiple tissues such as skin or brain infers that the initial amyloid protein may be produced locally in all organs affected or may, as observed in other human amyloidoses, be derived from a common circulating precursor (Joachim et al., [@B6]). Therefore the transdermal β-amyloid immunization also directly targeting skin β-amyloid deposits may further reduce a potential source for amyloid precursors to other organs such as the brain.
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